Kolexia
Derbel Miled Olfa Oncologie médicale
Derbel Miled Olfa
Oncologie médicale
Selarl Oncologie Beal Derbel Bally
Lyon, France
114 Activités
548 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Sarcomes Carcinomes Tumeurs de l'ovaire Neutropénie Adénocarcinome Tumeurs de la thyroïde Lymphopénie Tumeurs du rectum

Collaborateurs

Voir plus
Tredan Olivier
Tredan Olivier
Centre Léon-Bérard, Lyon, France
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France
Ray Isabelle
Ray Isabelle
Centre Léon-Bérard, Lyon, France
Heudel Pierre Etienne
Heudel Pierre Etienne
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
Novartis
30 collaboration(s)
Dernière en 2023
Daiichi Sankyo
20 collaboration(s)
Dernière en 2023
Pfizer
17 collaboration(s)
Dernière en 2023
A+A
16 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
180P Immunogenomic profiling of the randomized NeoPembrOv clinical trial reveals the VEGFR2 angiogenic axis as a promising actionable target to overcome immunoresistance of high-grade ovarian carcinomas
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023
InTTercePT: Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression
Essai Clinique (Seagen)   21 septembre 2023
PADA-1: Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients
Essai Clinique (Pfizer)   21 septembre 2023
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study.
Breast cancer (Dove Medical Press)   27 avril 2023
BREASTIMMU02: A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients
Essai Clinique (Amgen)   09 janvier 2023
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
The Lancet. Oncology   29 septembre 2022
Top Santé - Cancer du sein : de si grand progrès
Youtube @ Ramsay Santé   01 juillet 2022
Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy (CT) with or without pembrolizumab (P) followed by interval debulking surgery and standard systemic therapy ± P for advanced high-grade serous carcinoma (HGSC): A GINECO study.
2021 ASCO Annual Meeting I   28 mai 2021